Sunday, August 21, 2016

23andMe's Consumer DNA Data Goldmine Is Starting To Pay Off

The consumer genetic testing company says it can barely keep up with demand from researchers, while patient advocates wonder if customers deserve a cut of the profits.


The consumer genetic testing company says it can barely keep up with demand from researchers, while patient advocates wonder if customers deserve a cut of the profits.

After decades of inconclusive results, researchers backed by Pfizer and Massachusetts General Hospital revealed that they had identified several genetic markers associated with depression earlier this month. It was the largest study of its kind, using data from more than 120,000 people.

Read Full Story



No comments:

Post a Comment